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Abstract. The therapeutic efficacy for chronic prosta-
titis/chronic pelvic pain syndrome (CP/CPPS) is currently 
unsatisfactory. The aim of the present study was to assess the 
safety and efficacy of pollen extract in association with vita-
mins (DEPROX 500®) in males with CP/CPPS. All patients 
with a diagnosis of CP/CPPS attending the same urologic 
centre between March and October 2012 were enrolled in 
this randomised controlled phase III study. Participants were 
randomised to receive oral capsules of DEPROX 500® (two 
capsules every 24 h) or ibuprofen (600 mg, one tablet three 
times a day) for four weeks. The National Institutes of Health 
Chronic Prostatitis Symptom Index (NIH‑CPSI), International 
Prostate Symptom Score and Quality of Well-Being (QoL) 
questionnaires were used. In the intention-to-treat analysis, 
87 males (25 class IIIa and 62 class IIIb) with a mean age of 
33.6±5.9 years were randomly allocated to the DEPROX 500® 
(n=41) or ibuprofen (n=46) treatment groups. At the follow-up 
examination (following one month of treatment), in the 
DEPROX 500® group, 31/41 patients (75.6%) reported an 
improvement in quality of life, defined as a reduction of the 
NIH-CPSI total score by ≥25%, compared with 19/46 (41.3%) 
in the control group (P=0.002). The greater improvement in the 
DEPROX 500® group compared with the ibuprofen group was 
statistically significant (treatment difference in the NIH‑CPSI 
pain domain, -2.14±0.51, P<0.001; QoL scores, P=0.002). All 
patients were negative at the Meares-Stamey test evaluation. 
Adverse events were less frequent in the DEPROX 500® group 
than in the ibuprofen group. The DEPROX 500® treatment 
significantly improved total symptoms, pain and quality of life 
compared with ibuprofen in patients with CP/CPPS, without 
severe side-effects.
Introduction
Chronic prostatitis (CP) has been described as one of the 
most common illnesses in males aged <50 years (1), and 
exhibits different clinical presentations (2). According to the 
classification of the National Institutes of Health (NIH) (3), 
class III CP/chronic pelvic pain syndrome (CP/CPPS) is the 
most frequent category (4), in which either genitourinary 
symptoms or pain are usually found and the impact on quality 
of life is considerable (5). The efficacies of current therapies 
for CP/CPPS are unsatisfactory (6). Phytotherapeutics are a 
noteworthy option due to their generally minimal side-effects; 
however, few have been subjected to scientific scrutiny and 
prospective controlled clinical trials (7,8). In previous years, a 
number of studies have shown that pollen extract preparations 
are able to yield a durable and marked reduction of symptoms 
in young males with CP/CPPS, with an improvement in 
semen quality and a significant reduction in the NIH-Chronic 
Prostatitis Symptom Index (CPSI) score (9‑11). Previously, 
Wagenlehner et al demonstrated that a standardized pollen 
extract significantly improved the total symptoms, pain and 
Quality of Well‑Being (QoL) scores in patients with inflamma-
tory CP/CPPS without severe side-effects, highlighting the role 
of the anti-inflammatory activity of pollen extract (12). In the 
last year, Cai et al demonstrated that pollen extract in associa-
tion with vitamins significantly improved the total symptoms, 
pain and QoL scores in patients with non-inflammatory 
CP/CPPS without severe side-effects in a phase II study (10). 
Furthermore, the association with vitamins is likely to improve 
the antioxidant activity of the pollen extract as well as the 
protective effect on nerves and also reduce the pain in patients 
with inflammatory or non‑inflammatory CP/CPPS (10). The 
aim of the present study was to assess the safety and efficacy of 
pollen extract in association with vitamins in comparison with 
ibuprofen in order to improve the quality of life of patients 
affected by CP/CPPS by the relief of pain.
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Materials and methods
Study design. In order to assess the safety and efficacy of 
pollen extract in association with vitamins (DEPROX 500®) 
in males with CP/CPPS, all consecutive patients with a clin-
ical and instrumental diagnosis of CP/CPPS (class IIIa or b), 
attending the same urologic centre (Santa Chiara Regional 
Hospital, Trento, Italy) between March and October 2012 
were screened for this prospective randomised controlled 
phase III study. The design of the study was in accordance 
with the guidelines for clinical trials in CP/CPPS described 
by the NIH Chronic Prostatitis Collaborative Research 
Network (13). No placebo arm was included. The possible 
biases caused by the lack of placebo arm were considered in 
the results analysis. No placebo run-in period was considered 
necessary due to the fact that all enrolled patients were not 
blinded. The main outcome measure was the improvement of 
quality of life at the end of the whole study period, defined 
as the symptomatic improvement in the pain domain of the 
NIH‑CPSI. Clinical failure was defined as the persistence 
of low quality of life following the treatment (failure to 
obtain a reduction of the NIH-CPSI total score by ≥25%), 
or the suspension of therapy for significant reported adverse 
effects (12). In addition, spontaneously reported adverse 
events, or those noted by the investigator, were recorded 
during the whole study period. The study was conducted in 
line with Good Clinical Practice guidelines, with the ethical 
principles laid down in the latest version of the Declaration 
of Helsinki. Written informed consent was obtained from 
all patients prior to treatment. Furthermore, this study 
was conducted in line with the Consolidated Standards of 
Reporting Trials statement (The Ottawa Hospital Research 
Institute, Ottawa, ON, Canada).
Study schedule. On arrival at the center, all eligible 
individuals provided their written informed consent and 
underwent baseline questionnaires, urological examination 
and the Meares-Stamey test that was performed by the same 
urologist in accordance with the procedure described in the 
European Association of Urology (EAU) guidelines (14). 
All patients who met the inclusion criteria undertook oral 
administration of DEPROX 500® (two capsules every 24 h) 
or ibuprofen (600 mg, one tablet three times a day) for four 
weeks. Ibuprofen was selected in accordance with the results 
obtained by Lee et al (15). Proton-pump inhibitors (PPIs) 
were not routinely used due to the fact that all patients with 
gastrointestinal bleeding or a history of duodenal or gastric 
ulcers were excluded. Enrolled patients were not blinded to 
the preventative treatment. All patients were assigned to the 
two groups (DEPROX 500® and ibuprofen) according to a 
1:1 randomization (Fig. 1). All patients were contacted by 
telephone on day 14 of the therapy to ensure correct timing 
and dose of treatment. Each subject was scheduled for a 
follow‑up examination at 30 days from starting therapy, with a 
urological and microbiological examination and questionnaire 
collection.
Inclusion and exclusion criteria. Inclusion criteria were the 
presence of symptoms of pelvic pain for at least three months 
during the six months before study entry, according to the EAU 
guidelines, a score in the pain domain of the NIH-CPSI (14) 
of >7 and a negative four-glass result in the Meares-Stamey 
test (12). Subjects <18 and >65 years of age, affected by major 
concomitant diseases, with known anatomical abnormalities of 
the urinary tract or with evidence of other urological diseases, 
and with residual urine volume >50 ml resulting from bladder 
outlet obstruction were excluded. Males with a reported 
allergy to pollen extract, who had recently (<4 weeks) 
undergone oral or parental treatment or who were currently 
using prophylactic antibiotic drugs were also excluded. 
Additionally, all patients with a history of gastrointestinal 
bleeding or duodenal or gastric ulcers were excluded. All 
patients positive to tests for Chlamydia trachomatis (Ct), 
Ureaplasma urealyticum, Neisseria gonorrhoeae, herpes 
viruses (HSV 1/2) and human papillomavirus (HPV) were 
also excluded.
Composition and characterization of the extracts used. All 
patients who were randomized to the DEPROX 500® group 
underwent oral administration of two tablets of DEPROX 500® 
in a single dose daily in the evening, in line with our previous 
study (10) and with the manufacturer's instructions (IDI 
Integratori Dietetici Italiani S.r.l, Sicily, Italy). Each admin-
istration contained 1 g pollen extract (500 mg per tablet), 
and vitamins B1, B2, B6, B9, B12 and PP. All compound 
analyses were carried out in accordance with the procedures 
described by Fiamegos et al (16). All patients randomized to 
the ibuprofen group received ibuprofen (600 mg) three times 
per day.
Questionnaires and urological examinations. The validated 
Italian versions of the NIH-CPSI (17) and the International 
Prostate Symptom Score (IPSS) (18) questionnaires were 
administered to each patient. The questionnaires were 
self-administered when the patient arrived at the urologic 
centre. Furthermore, patient quality of life was measured 
by using an Italian version of the QoL scale, a validated, 
multi-attribute health scale (19). This scale was selected 
because it has been successfully applied to acute illnesses, 
whereas other quality of life scales, including the Short 
Form-36 (SF-36) Health Survey, are more suitable in chronic 
cases (20). Higher scores on the QoL scale reflect a higher 
quality of life. In accordance with the study by Nickel et al (21), 
prostatitis‑like symptoms were considered significant at a pain 
Figure 1. Study schedule. V1 = baseline, V2 = follow-up visit at 30 days. 
q, every.
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score of ≥4. The NIH‑CPSI was also used in determining 
clinical therapy efficacy (21).
Sample collection and laboratory procedures. All samples 
were collected during the urological examination and imme-
diately taken to the laboratory, under refrigerated conditions, 
analysed for cultures and aliquoted for DNA extraction and 
polymerase chain reaction for Ct, Neisseria gonorrhoeae, 
HSV 1/2 and HPV detection. All subjects included in the 
study underwent urinary culture for common bacteria, yeasts 
and urogenital mycoplasma. Microbiological culture was 
carried out in accordance with the methods described by 
Mazzoli et al (22). DNA extraction and purification from urine 
were performed using the EZ1 DNA Tissue kit (Qiagen SpA, 
Milan, Italy), as described in our previous study (22).
Statistical analysis. The primary target of the study was 
the symptomatic improvement in the pain domain of the 
NIH-CPSI. In order to analyse the homogeneity of the two 
groups, the baseline characteristics were compared using 
the Student's t-test and Mann‑Whitney U test for continuous 
variables and by the χ2 test for categorical variables. The 
normal distribution of the variables was assessed using the 
Kolmogorov-Smirnov test. Data were analysed based on the 
intention-to-treat (ITT) approach. General characteristics of 
the study participants were expressed using descriptive statis-
tics (means, standard deviations and ranges). The required 
sample size for the present study was calculated under the 
following conditions: Difference between the groups, 2±1 
score points in the NIH-CPSI pain domain; α error level, 0.05 
two-sided; statistical power, 80%; and anticipated effect size, 
Cohen's d=0.5. The calculation yielded 2x39 individuals per 
group. Randomization based on a single sequence of random 
assignments (simple randomization) was performed using 
a pseudo-random number generator software (Research 
Randomizer Version 4.0, Social Psychology Network, 
Wesleyan University, Middletown, CT, USA). Analysis 
of variance (ANOVA) was used for comparing the means. 
The Bonferroni adjustment test was also used at the second 
stage of the ANOVA. The effect size between the means 
(Cohen's d) was also calculated. The differences between the 
groups regarding the NIH-CPSI results were obtained using 
an ANOVA test. Statistical significance was achieved when 
P<0.05. All reported P-values were two-sided. Statistical 
analyses were performed using SPSS software, version 11.0 
(SPSS, Inc., Chicago, IL, USA) for Apple-Macintosh.
Results
Patients. From the 115 patients attending the center for 
prostatitis-like symptoms during the study period, 94 were 
eventually enrolled and randomised. Out of the 21 patients 
excluded from the study, eight refused to be enrolled, six 
reported adverse effects to nonsteroidal anti‑inflammatory 
drugs, two reported a clinical history of gastrointestinal ulcers 
and five elected to be treated in other centres. Additionally, 
seven patients were lost subsequent to randomisation and 
87 males were finally enrolled (Fig. 2). The baseline question-
naire mean scores were 25.9±2.1, 8.0±3.6 and 0.55±0.15 for 
NIH-CPSI, IPSS and QoL, respectively. Historical medical 
information and clinical data at enrolment are described in 
Table I. No statistically significant differences between the 
groups were identified.
Randomisation. Of the 87 enrolled patients (mean age 33.6±5.9 
years), 41 received DEPROX 500® (group A), and 46 received 
600 mg ibuprofen (group B). The treatment arms were compa-
rable for all variables at the enrolment and randomisation 
visits.
Compliance with treatment schedule and adverse effects. In 
group A, 1/41 patients (2.4%) had mild adverse effects that did 
not require additional treatment (nausea), while in group B, 
7/46 patients (15.2%) reported nausea and epigastric pain. In 
group A, 40 patients (97.5%) were analysed subsequent to 
one being lost in follow-up. In group B, 38 patients (82.6%) 
were analysed subsequent to two being lost to follow-up and 
four discontinuing therapy due to gastrointestinal adverse 
effects. The DEPROX 500® treatment was well tolerated 
in all the patients analysed, and no significant drug‑related 
side‑effects were identified. The analyses were carried out 
in the ITT (pollen extract, n=41; ibuprofen, n=46) and per 
protocol (PP) populations (pollen extract, n=40; ibuprofen, 
n=40) (Fig. 2).
Clinical and laboratory results at follow‑up (after one month 
of treatment). At the follow‑up examination, in the ITT set 
and DEPROX 500® group, 31/41 patients (75.6%) reported an 
improvement of quality of life, defined as a reduction of the 
NIH-CPSI total score by ≥25%, compared with 19/46 (41.3%) in 
the control group (P=0.002). In the PP set and DEPROX 500® 
group, 31/40 patients (77.5%) reported an improvement of 
quality of life, compared with 20/40 (50.0%) in the control 
group (P=0.019). The questionnaire results at one month 
after treatment were as follows: NIH-CPSI, 12.8±2.20; IPSS, 
7.6±1.58; and QoL, 0.69±0.10 in the DEPROX 500® group. 
By contrast the results in the control group were: NIH-CPSI, 
19.5±2.10; IPSS, 8.00±2.81; and QoL, 0.59±0.18. The higher 
improvement in the DEPROX 500® group compared with the 
ibuprofen group was statistically significant (treatment differ-
ence in NIH-CPSI pain domain: ITT, -2.14±0.51, P<0.001; PP, 
‑1.76±0.22, P<0.001). Statistically significant differences were 
also reported in the NIH-CPSI (P<0.001), and QoL (P=0.002) 
scores between the two visits in the DEPROX 500® group 
and between the two groups (Figs. 3 and 4). No statistically 
significant differences were identified in the IPSS scores 
(P=0.43). All patients were negative at the Meares-Stamey test 
evaluation. All questionnaire results at the follow-up visit are 
presented in Table II. The results of the physical examinations, 
including vital signs, and laboratory examinations showed no 
relevant changes from the baseline.
Sub‑analysis on the basis of CP/CPPS type. Of the 87 patients, 
25 (28.7%) showed inflammatory CP/CPPS (type IIIa), while 
62 (71.3%) exhibited type IIIb. A statistically significant 
difference was identified between the two groups in terms of 
pain relief and QoL improvement when stratified by CP/CPPS 
type. In fact, in the DEPROX 500® group, patients affected 
by type IIIb CP/CPPS showed higher QoL results and a lower 
pain level following treatment (the NIH-CPSI score was 
CAI et al:  POLLEN EXTRACT AND CHRONIC PELVIC PAIN RELIEF 1035
Table I. Baseline characteristics and clinical parameters at enrolment.
Parameter DEPROX 500® group Ibuprofen group
Patients, n 41 46
Age, yearsa 33.8±6.78 33.7±5.44
Marital status, n (%)
  Married 19 (46.3) 18 (39.1)
  Unmarried 22 (53.7) 28 (60.8)
Educational qualification, n (%)
  Primary school   5 (12.2) 7 (15.2)
  High school 29 (70.7) 27 (58.6)
  University   7 (17.1) 12 (26.2)
Smoker status, n (%)
  Yes 11 (26.8) 13 (28.2)
  No 30 (73.2) 33 (71.8)
Sexually active in the past month, n (%) 39 (95.1) 41 (89.1)
Sexual behaviour, n (%)
  1 partner 33 (80.4) 37 (80.4)
  >1 partners   8 (19.6) 9 (19.6)
Contraceptive use, n (%)
  Condom 29 (70.3) 34 (73.9)
  Coitus interruptus 12 (29.7) 12 (26.1)
Start of CP history (months)a 18.7±4.28 19.1±3.99
Symptoms score at baselinea
  NIH-CPSI 24.9±2.1 25.5±3.0
  IPSS   8.3±3.6   8.0±2.5
  QoL   0.57±0.17 0.55±0.15
Clinical presentation, n (%)
  Dysuria 12 (29.2) 14 (30.4)
  Urgency   4 (9.7)   5 (10.8)
  Dysuria + frequency   6 (14.6)   5 (10.8)
  Burning   7 (17.0)   9 (19.5)
Pain, n (%)
  Perineal 19 (46.4) 21 (45.6)
  Scrotal   4 (9.7)   4 (8.7)
  Suprapubic   8 (19.6)   9 (19.6)
  Lower abdominal 10 (24.3) 12 (26.1)
Pain frequency, n (%)
  Daily 33 (80.4) 36 (78.2)
  Weekly   8 (19.6) 10 (21.8)
Sexual Symptoms, n (%)
  ED 12 (29.2) 13 (28.2)
  PE   7 (17.0)   6 (13.0)
  ED + EP   4 (9.7)   4 (8.6)
CP/CPPS type, n (%)
  Type a 12 (29.2) 13 (28.2)
  Type b 29 (70.8) 33 (71.8)
aData are presented as the mean ± standard deviation. CP, chronic prostatitis; NIH-CPSI, National Institutes of Health-Chronic Prostatitis 
Symptom Index; IPSS, International Prostate Symptom Score; QoL, Quality of Well‑Being; CPPS, chronic pelvic pain syndrome; ED, erectile 
dysfunction; PE, premature ejaculation.
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24.8±1.8 at the enrolment versus 11.7±1.7 at the follow-up 
visit; P<0.001) when compared with type IIIa CP/CPPS 
patients (Table III). No differences were reported between the 
ITT or PP sets.
Discussion
The major finding of the present study was that DEPROX 500® 
is able to provide early pain relief and improve the quality of 
Figure 2. Study flow‑chart according to the Consolidated Standards of Reporting Trials statement. ITT, intention‑to‑treat; PP, per protocol analysis.
Figure 3. Statistically significant differences between the two visits in terms 
of the NIH-CPSI scores (P<0.001) between the two groups. NIH-CPSI, 
National Institutes of Health‑Chronic Prostatitis Symptom Index.
Figure 4. Statistically significant differences between the two visits in terms 
of the QoL scores (P=0.002) between the two groups. QoL, Quality of 
Well-Being.
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life in patients with CP/CPPS without severe side-effects, when 
compared with ibuprofen. Furthermore, it was revealed that 
patients affected by type IIIb CP/CPPS may obtain greater advan-
tages from this therapy. These findings lead to several points of 
discussion. Firstly, the early pain relief. In 2006, Elist (23), using 
a double-blind study with random distribution versus placebo, 
demonstrated the superiority of pollen extract versus placebo in 
terms of improvement in pain score and the filling and emptying 
symptoms from the start to the end of the treatment after six 
months of therapy. Additionally, in 2009, Wagenlehner et al (12) 
showed that pollen extract improved symptoms, pain and quality 
of life after 12 weeks of treatment in patients with this condition, 
with differences in favour of pollen extract at six weeks of treat-
ment compared with the placebo, and the treatment being well 
tolerated. These two studies treated the patients for at least six 
weeks (12,23). Consistent with our previous study (10), 30 days 
of treatment with DEPROX 500® in the present study was able 
to provide significant results in terms of pain reduction when 
compared with ibuprofen. This effect is possibly due to the 
association between the pollen extract and vitamins B6 and B12 
that improve the antioxidant activity of pollen extract with the 
protective effect on nerves. B vitamins including thiamine (B1), 
pyridoxine (B6) and cyanocobalamin (B12) are capable of anti-
nociception in experimental animals with acute and chronic pain 
evoked by electrical, chemical and thermal stimulation, primary 
neuronal injury and diabetes (24,25). Notably, several studies 
have demonstrated that certain B vitamins, particularly B6 and 
B12, are able to protect neurons from certain injuries (26,27). 
The B vitamins, B1, B6 and B12, are clinically useful in the 
treatment of certain painful conditions including lumbago, 
sciatica, trigeminal neuralgia and chronic pain associated with 
diabetic polyneuropathy (28). Finally, we hypothesized that the 
early improvement on pain relief is due to the protective effect on 
nerves, and the following improvement in quality of life could be 
due to the antioxidant activity of pollen extract. Indeed, previous 
studies in which only pollen extract was administered demon-
strated an improvement in quality of life and pain relief after 
≥6 weeks of treatment. Furthermore, on the basis of the sub-anal-
ysis, the patients that best obtained the important advantages 
from this therapy were those with non‑inflammatory CP/CPPS. 
Contrasting with previous studies, the present study revealed 
that patients with non‑inflammatory CP/CPPS showed improved 
results compared with those with inflammatory CP/CPPS. This 
is possibly due to the fact that the protective effect on nerves of 
B vitamins occurs earlier than the anti‑inflammatory effect of 
pollen extract. In this sense, DEPROX 500® is able to provide 
improved results in terms of early pain reduction in patients with 
non‑inflammatory CP/CPPS. DEPROX 500® was generally well 
tolerated over the full study period. 
The present study had a few limitations that should be 
taken into account: The small number of enrolled patients, a 
short follow-up period, a selected patient population, the lack 
of control group and that this was not a blinded study. Given 
the lack of prove efficacy of conventional therapies, alternative 
treatment options are urgently required and pollen extract in 
association with vitamins should be an noteworthy option due 
to its generally low side-effects and promising results in terms 
of quality of life improvement.
Table II. Questionnaire results at the follow-up visit.
Variable DEPROX 500® group Ibuprofen group
NIH-CPSI (P<0.001)a 12.8±2.20 19.5±2.10
IPSS (P=0.87)a   7.6±1.58 8.00±2.81
QoL (P=0.002)a 0.69±0.10 0.59±0.18
Reduction in NIH-CPSI pain domainb, n (%) 31 (77.5) 19 (47.5)
Efficacy outcomes (NIH‑CPSI pain domain)a,c -4.36±0.51 -2.22±0.53
Efficacy outcomes (NIH‑CPSI pain domain)a,d -3.86±0.21 -2.10±0.20
aData are presented as the mean ± standard deviation; bpain, P<0.003; cintention-to-treat analysis, treatment difference -2.41±0.51, P<0.001; 
dper protocol analysis, treatment difference ‑1.76±0.22, P<0.001. NIH‑CPSI, National Institutes of Health‑Chronic Prostatitis Symptom Index; 
IPSS, International Prostate Symptom Score; QoL, Quality of Well-Being.
Table III. Results of the sub-analysis on the basis of CP/CPPS 
type a or b.
Variable DEPROX 500® group Ibuprofen group
Patients, n  40 40
  Type a, n (%) 14 (35) 11 (27.5)
  Type b, n (%) 29 (65) 32 (72.5)
NIH-CPSIa
  Type a 13.1±1.8 20.2±1.9
  Type b  11.7±1.7 19.1±2.7
IPSSa
  Type a 7.9±0.9 7.9±3.1
  Type b 7.4±1.5 8.0±2.2
QoLa
  Type a 0.61±0.3 0.57±0.2
  Type b 0.70±0.1 0.60±0.1
aData are presented as the mean ± standard deviation. NIH-CPSI, 
National Institutes of Health‑Chronic Prostatitis Symptom Index; 
IPSS, International Prostate Symptom Score; QoL, Quality of 
Well-Being; CP/CPPS, chronic prostatitis/chronic pelvic pain syn-
drome.
EXPERIMENTAL AND THERAPEUTIC MEDICINE  8:  1032-1038,  20141038
In conclusion, given the aforementioned limitations, 
DEPROX 500® significantly improved the total symptoms, 
pain, and quality of life compared with ibuprofen in patients 
with CP/CPPS, without severe side-effects.
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